VANDA PHARMACEUTICALS INC. Additional Paid in Capital, Common Stock
VANDA PHARMACEUTICALS INC. (VNDA) had Additional Paid in Capital, Common Stock of $725.93 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $725.93M.
- 2026-03-31: Additional Paid in Capital, Common Stock $723.83M.
- 2025-12-31: Additional Paid in Capital, Common Stock $721.26M.
- 2025-09-30: Additional Paid in Capital, Common Stock $718.98M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $725.93M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $723.83M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $721.26M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $718.98M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $716.87M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $714.76M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $712.71M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $709.84M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $706.84M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $703.86M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $700.27M 10-K · filed 2025-02-14 | |
| 2023-09-30 | $697.00M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $693.84M 10-Q · filed 2023-07-28 | |
| 2023-03-31 | $690.59M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $686.24M 10-K · filed 2024-02-08 | |
| 2022-09-30 | $681.85M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $677.96M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $674.00M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $669.22M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $664.41M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $660.09M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $656.06M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $650.30M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $645.66M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $642.40M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $635.73M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $631.31M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $625.52M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $621.56M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $615.05M 10-Q · filed 2019-05-03 | |
| 2018-12-31 | $611.59M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $607.87M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $604.89M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $599.48M 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $492.80M 10-K · filed 2019-02-19 | |
| 2017-09-30 | $489.94M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $486.40M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $481.55M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $477.09M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $474.23M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $466.27M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $463.08M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $460.79M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $458.91M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $453.27M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $450.61M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $448.74M 10-K · filed 2016-02-12 | |
| 2014-09-30 | $358.73M 10-Q · filed 2014-10-27 | |
| 2014-06-30 | $357.12M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $355.64M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $352.24M 10-K · filed 2015-03-13 | $355.43M 10-K · filed 2014-02-25 |
| 2013-09-30 | $353.71M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $303.36M 10-Q · filed 2013-07-31 | |
| 2013-03-31 | $301.73M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $300.97M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $300.04M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $299.46M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $298.27M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $296.87M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $295.53M 10-Q · filed 2011-11-07 | |
| 2011-06-30 | $294.27M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $291.34M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |